Therefore, inhibiting ex-vivo leukotriene B4 (LTB 4), which induced Mac-1 (CD11b/CD18) expression in leucocytes of patients with RA disease, could change the clinical signs and symptoms of the RA disease (21). This evidence concerns the gene ITGAM and rheumatoid arthritis.